Related Experiment Videos
Paraneoplastic hypercalcemia in endometrial carcinoma
N Hiller1, M Sonnenblick, C Hershko
1Department of Medicine, Shaare Zedek Medical Center, Jerusalem, Israel.
Oncology
|January 1, 1989
Summary
Humoral hypercalcemic syndrome, a rare complication of uterine tumors, may be underdiagnosed. Increased awareness can lead to earlier detection of this metabolic issue in clear cell adenocarcinoma.
Area of Science:
- Gynecologic Oncology
- Endocrinology
- Oncologic Emergencies
Background:
- Humoral hypercalcemic syndrome (HHS) is rarely associated with gynecologic malignancies.
- Fewer than 30 cases were documented before 1980.
Observation:
- Two patients with clear cell adenocarcinoma of the uterus presented with HHS.
- Hypercalcemia ranged from 12.8 to 14.1 mg/dl.
- Patients had normal parathyroid hormone levels, reduced phosphate reabsorption, and low albumin.
Findings:
- The study identified two new cases of HHS in uterine clear cell adenocarcinoma.
- The findings suggest HHS may be more common in uterine malignancies than previously thought.
Implications:
- Early diagnosis of HHS in uterine cancer patients is crucial.
- Increased clinical awareness can improve management of this metabolic complication.
- This highlights the importance of monitoring calcium levels in gynecologic cancer patients.